Oncogenic ADAM28 induces gemcitabine resistance and predicts a poor prognosis in pancreatic cancer

doi:10.3748/wjg.v25.i37.5590

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 25, Issue 37

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (10203)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-6) series.

Item

Count

PDF

791

WORD

229

HTML

6407

Figures (1-6)

339

Sum=7766

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

882

Download

1555

Sum=2437

Oct 7, 2019 (publication date) through Dec 22, 2024

Times Cited of This Article

Times Cited (25)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Gastroenterol. Oct 7, 2019; 25(37): 5590-5603
Published online Oct 7, 2019. doi: 10.3748/wjg.v25.i37.5590

Full Size Figure Download Figure

Figure 4 Overall survival and relapse-free survival evaluated between pancreatic cancer patients with high and low expression of ADAM28. A: OS of pancreatic cancer patients from TCGA; B: RFS of pancreatic cancer patients from TCGA; C: OS of pancreatic cancer patients with high TMB between the high and low ADAM28 expression cohorts; D: OS of pancreatic cancer patients with low TMB between the high and low ADAM28 expression cohorts. OS: Overall survival; RFS: Relapse-free survival; TMB: Tumor mutation burden; TCGA: The Cancer Genome Atlas.

Citation: Wei L, Wen JY, Chen J, Ma XK, Wu DH, Chen ZH, Huang JL. Oncogenic ADAM28 induces gemcitabine resistance and predicts a poor prognosis in pancreatic cancer. World J Gastroenterol 2019; 25(37): 5590-5603
URL: https://www.wjgnet.com/1007-9327/full/v25/i37/5590.htm
DOI: https://dx.doi.org/10.3748/wjg.v25.i37.5590